Allarity Therapeutics
ALLR
2 hedge funds and large institutions have $33.3K invested in Allarity Therapeutics in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
723% more capital invested
Capital invested by funds: $4.05K → $33.3K (+$29.3K)
0.11% more ownership
Funds ownership: 0% → 0.11% (+0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$71.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$23.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$32 |
| 2 |
Morgan Stanley
New York
|
-$7 |
ALLR Hedge Fund Activity: Q2 2023 in Review
2 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in Allarity Therapeutics (ALLR) for Q2 2023, worth a combined $33.3K — up 723% from $4.05K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new ALLR positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $71.3K. The largest seller was Bank of America, cutting an estimated $32.
- 2 institutional investors held Allarity Therapeutics (ALLR) as of Q2 2023, up from 0 in Q1 2023.
- Funds reported $33.3K of Allarity Therapeutics stock for Q2 2023, up 723% quarter-over-quarter.
- 2 funds opened new Allarity Therapeutics positions in Q2 2023 and 0 closed out, a net change of +2 holders.
- The largest Allarity Therapeutics buyer in Q2 2023 was UBS Group, an estimated $71.3K added.
- The largest Allarity Therapeutics seller in Q2 2023 was Bank of America, an estimated $32 sold.
Based on aggregated 13F filings for Q2 2023.